Ginkgo Bioworks Holdings (DNA) Non-Current Deffered Revenue (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Non-Current Deffered Revenue for 7 consecutive years, with $76.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Deffered Revenue rose 2.64% year-over-year to $76.5 million; the trailing twelve-month figure through Jun 2026 stood at $76.5 million (up 2.64% YoY), and the FY2025 full-year result was $75.2 million, down 23.89% from the prior year.
• Non-Current Deffered Revenue eased to $76.5 million in Q2 2026 per DNA's latest filing, from $77.9 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $179.9 million in Q2 2023 and bottomed at $74.1 million in Q3 2025.
• Historically, Non-Current Deffered Revenue has averaged $128.7 million across 5 years, with a median of $151.8 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue jumped 181.87% in 2022, then plunged 51.6% in 2025.
• Over 5 years, Non-Current Deffered Revenue stood at $174.8 million in 2022, then decreased by 9.56% to $158.1 million in 2023, then tumbled by 37.5% to $98.8 million in 2024, then retreated by 23.89% to $75.2 million in 2025, then increased by 1.8% to $76.5 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $76.5 million, $77.9 million, and $75.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.